

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**EXERCISE OF PART OF THE SHARE OPTIONS GRANTED UNDER
THE ADJUSTED INITIAL GRANT OF THE 2019 A SHARE
INCENTIVE PLAN FOR THE FIRST VESTING PERIOD
DURING THE FIRST QUARTER OF 2022**

References are made to (i) the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated July 19, 2019; (ii) the circular of the Company dated August 5, 2019 (the “**Circular**”); (iii) the poll results announcement of the Company dated September 20, 2019; (iv) the announcement of the Company dated September 30, 2019; (v) the circular of the Company dated October 4, 2019; (vi) the poll results announcement of the Company dated November 18, 2019; (vii) the announcements of the Company dated November 25, 2019, June 10, 2020, October 19, 2020, April 28, 2021, June 3, 2021, June 25, 2021, July 1, 2021, October 8, 2021 and January 4, 2022 (collectively, the “**Announcements**”) in relation to, among other things, (a) the adoption of the 2019 A Share Incentive Plan; (b) the adoption of the list of Incentive Participants of the 2019 A Share Incentive Plan; (c) the adjustments to the number of Incentive Participants and Share Options to be granted under the initial grant of the 2019 A Share Incentive Plan; (d) the cancellation of part of the Share Options granted under the 2019 A Share Incentive Plan; (e) the fulfillment of vesting conditions for the First Vesting Period of the Share Options granted under the 2019 A Share Incentive Plan; and (f) the exercise of part of the Share Options granted under the Adjusted Initial Grant of the 2019 A Share Incentive Plan for the First Vesting Period during the second quarter, the third quarter and the fourth quarter of 2021. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcements.

EXERCISE OF PART OF THE SHARE OPTIONS GRANTED UNDER THE ADJUSTED INITIAL GRANT OF THE 2019 A SHARE INCENTIVE PLAN FOR THE FIRST VESTING PERIOD DURING THE FIRST QUARTER OF 2022

As disclosed in the announcement of the Company dated June 3, 2021, the exercise conditions for the First Vesting Period of the Share Options granted under the Adjusted Initial Grant have been fulfilled. The First Vesting Period of the Share Options granted under the Adjusted Initial Grant shall be from June 9, 2021 to May 25, 2022.

As at March 31, 2022, 363 Incentive Participants have exercised part of the Share Options granted to them under the Adjusted Initial Grant for the First Vesting Period at their discretion, the details of which are set out below:

| Position | Number of exercisable Share Options granted under the Adjusted Initial Grant of the 2019 A Share Incentive Plan for the First Vesting Period | Number of Share Options exercised during the first quarter of 2022 | Number of Share Options exercised as at March 31, 2022 | Percentage to |
|---|--|--|--|--|
| | | | | the total number of exercisable Share Options granted under the Adjusted Initial Grant of the 2019 A Share Incentive Plan for the First Vesting Period |
| Senior management, mid-level managers and backbone members of the technicians, basic level managers and other technicians | 2,868,385 | 135,349 | 2,666,528 | 92.96% |

The underlying shares of the exercised Share Options are new ordinary A Shares issued by the Company to the Incentive Participants (the “**Underlying A Shares**”). The Company has completed the registration of the Underlying A shares with the Shanghai Branch of the China Securities Depository and Clearing Corporation Limited. The Underlying A Shares were credited to the respective securities accounts of the Incentive Participants on the first trading day (T + 1) after the date of exercise of the Share Options (T), while trading in the Underlying A Shares shall commence on the trading day thereafter (T + 2).

CHANGES IN THE SHAREHOLDING STRUCTURE OF THE COMPANY

Unit: Share

| | Before the Change (as at December 31, 2021) | Change ^(Note 1) | After the Change (as at March 31, 2022) |
|--|--|-----------------------------------|--|
| A Shares with restricted conditions | 16,852,673 | -435,086 | 16,417,587 |
| A Shares without restricted conditions | 2,546,874,079 | 353,052 | 2,547,227,131 |
| H Shares | 392,100,147 | 71,124 | 392,171,271 |
| Total | <u>2,955,826,899</u> | <u>-10,910</u> | <u>2,955,815,989</u> |

Notes:

- The change in shareholding structure of the Company has taken into account (i) the repurchase and cancellation of part of the Restricted A Shares granted under the 2018 A Share Incentive Plan and the 2019 A Share Incentive Plan, as well as the unlocking and trading of the Restricted A Shares granted under the Special Grant and the Reserved Grant of the 2019 A Share Incentive Plan (the details of which are set out in the announcements of the Company dated January 11, 2022, January 14, 2022, February 23, 2022 and March 17, 2022); (ii) the exercise of part of the Share Options granted under the Adjusted Initial Grant of the 2019 A Share Incentive Plan for the First Vesting Period as disclosed in this announcement; and (iii) the issuance of new H Shares pursuant to the conversion of US\$300 million zero coupon convertible bonds due 2024 as disclosed in the relevant next day disclosure return of the Company dated January 18, 2022.
- The actual controller of the Company will remain unchanged after such changes in the shareholding structure of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, April 1, 2022

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*